Logo image of XCUR

EXICURE INC (XCUR) Stock Fundamental Analysis

NASDAQ:XCUR - Nasdaq - US30205M3097 - Common Stock - Currency: USD

11.36  +0.06 (+0.53%)

After market: 11.36 0 (0%)

Fundamental Rating

2

Taking everything into account, XCUR scores 2 out of 10 in our fundamental rating. XCUR was compared to 568 industry peers in the Biotechnology industry. XCUR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XCUR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XCUR has reported negative net income.
XCUR had a negative operating cash flow in the past year.
In the past 5 years XCUR always reported negative net income.
In the past 5 years XCUR always reported negative operating cash flow.
XCUR Yearly Net Income VS EBIT VS OCF VS FCFXCUR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

XCUR has a Return On Assets of -64.43%. This is in the lower half of the industry: XCUR underperforms 62.68% of its industry peers.
The Return On Equity of XCUR (-143.25%) is worse than 62.15% of its industry peers.
Industry RankSector Rank
ROA -64.43%
ROE -143.25%
ROIC N/A
ROA(3y)-73.86%
ROA(5y)-68.98%
ROE(3y)-239.53%
ROE(5y)-266.21%
ROIC(3y)N/A
ROIC(5y)N/A
XCUR Yearly ROA, ROE, ROICXCUR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

XCUR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XCUR Yearly Profit, Operating, Gross MarginsXCUR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K

More info and screens

6

2. Health

2.1 Basic Checks

XCUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XCUR has more shares outstanding
Compared to 5 years ago, XCUR has more shares outstanding
There is no outstanding debt for XCUR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XCUR Yearly Shares OutstandingXCUR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
XCUR Yearly Total Debt VS Total AssetsXCUR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -13.56, we must say that XCUR is in the distress zone and has some risk of bankruptcy.
XCUR has a worse Altman-Z score (-13.56) than 79.23% of its industry peers.
XCUR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.56
ROIC/WACCN/A
WACC10.29%
XCUR Yearly LT Debt VS Equity VS FCFXCUR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 4.45 indicates that XCUR has no problem at all paying its short term obligations.
The Current ratio of XCUR (4.45) is comparable to the rest of the industry.
XCUR has a Quick Ratio of 4.45. This indicates that XCUR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of XCUR (4.45) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.45
Quick Ratio 4.45
XCUR Yearly Current Assets VS Current LiabilitesXCUR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for XCUR have decreased strongly by -45.96% in the last year.
The Revenue for XCUR have been decreasing by -17.40% on average. This is quite bad
EPS 1Y (TTM)-45.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y-17.4%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XCUR Yearly Revenue VS EstimatesXCUR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 0 5M 10M 15M 20M 25M
XCUR Yearly EPS VS EstimatesXCUR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XCUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XCUR Price Earnings VS Forward Price EarningsXCUR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XCUR Per share dataXCUR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

XCUR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXICURE INC

NASDAQ:XCUR (4/22/2025, 6:44:57 PM)

After market: 11.36 0 (0%)

11.36

+0.06 (+0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/amc
Earnings (Next)06-16 2025-06-16
Inst Owners11.83%
Inst Owner Change0%
Ins Owners16.64%
Ins Owner Change0%
Market Cap71.80M
Analysts43.33
Price TargetN/A
Short Float %3.25%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 143.59
P/FCF N/A
P/OCF N/A
P/B 10.6
P/tB 10.6
EV/EBITDA N/A
EPS(TTM)-4.15
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.08
BVpS1.07
TBVpS1.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.43%
ROE -143.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.86%
ROA(5y)-68.98%
ROE(3y)-239.53%
ROE(5y)-266.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.45
Quick Ratio 4.45
Altman-Z -13.56
F-Score6
WACC10.29%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-45.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220.7%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y-17.4%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y64.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y71.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.9%
OCF growth 3YN/A
OCF growth 5YN/A